Bret Daniels, MD | |
6415 Lincoln Hwy, Wrightsville, PA 17368-9697 | |
(717) 252-1200 | |
(717) 252-0259 |
Full Name | Bret Daniels |
---|---|
Gender | Male |
Speciality | Family Practice |
Experience | 35 Years |
Location | 6415 Lincoln Hwy, Wrightsville, Pennsylvania |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1376516906 | NPI | - | NPPES |
0015801390003 | Medicaid | PA | |
0824775000 | Other | PA | AMERIHEALTH |
20029552 COLUMBIA | Other | PA | MERCY |
PCP P002659 | Other | PA | GATEWAY |
1136939 | Other | PA | KEYSTONE MERCY |
PCP-000000138812 | Other | PA | UNISON |
80100827 | Other | PA | RAILROAD MEDICARE |
0015801390008 | Medicaid | PA | |
50049084 | Other | PA | CAPITAL BLUE CROSS |
5067439 | Other | PA | AETNA PPO |
800768 | Other | PA | HIGHMARK BLUE SHIELD |
0015801390007 | Medicaid | PA | |
20030976 WRIGHTS | Other | PA | MERCY |
3264144 | Other | PA | AETNA HMO |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | MD57402L (Pennsylvania) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Lancaster General Hospital | Lancaster, PA | Hospital |
York Hospital | York, PA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Lancaster General Health - Columbia Center | 1254241359 | 22 |
News Archive
Gilead Sciences today announced topline results from two Phase 3 studies, FISSION and NEUTRINO, evaluating a 12-week course of the once-daily nucleotide sofosbuvir in combination with ribavirin (FISSION) and in combination with ribavirin and pegylated interferon (NEUTRINO) among treatment-naïve patients with chronic hepatitis C virus (HCV) infection.
Patients seeking to conserve privacy and personal dignity - i.e. anyone who's ever been forced to wear a traditional hospital gown that often reveal too much - may soon bid adieu peek-a-book hospital garb. Indeed, researchers from the University of Montreal have designed a revolutionary healthcare garment that preserves modesty.
Following a recent recall of potentially contaminated non-sterile alcohol prep pads, the U.S. Food and Drug Administration today reminded health care professionals about the safe use of non-sterile alcohol prep pads to clean and disinfect the surface of the skin.
Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine, have announced the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever study using patients' cells carrying an engineered T cell receptor to treat HIV (SL9 HA-GAG-TCR). The trial may have important implications in the development of new treatments for HIV potentially slowing – or even preventing – the onset of AIDS.
› Verified 6 days ago
Entity Name | Lancaster General Health - Columbia Center |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1700972338 PECOS PAC ID: 1254241359 Enrollment ID: O20040128000813 |
News Archive
Gilead Sciences today announced topline results from two Phase 3 studies, FISSION and NEUTRINO, evaluating a 12-week course of the once-daily nucleotide sofosbuvir in combination with ribavirin (FISSION) and in combination with ribavirin and pegylated interferon (NEUTRINO) among treatment-naïve patients with chronic hepatitis C virus (HCV) infection.
Patients seeking to conserve privacy and personal dignity - i.e. anyone who's ever been forced to wear a traditional hospital gown that often reveal too much - may soon bid adieu peek-a-book hospital garb. Indeed, researchers from the University of Montreal have designed a revolutionary healthcare garment that preserves modesty.
Following a recent recall of potentially contaminated non-sterile alcohol prep pads, the U.S. Food and Drug Administration today reminded health care professionals about the safe use of non-sterile alcohol prep pads to clean and disinfect the surface of the skin.
Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine, have announced the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever study using patients' cells carrying an engineered T cell receptor to treat HIV (SL9 HA-GAG-TCR). The trial may have important implications in the development of new treatments for HIV potentially slowing – or even preventing – the onset of AIDS.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Bret Daniels, MD 6415 Lincoln Hwy, Wrightsville, PA 17368-9697 Ph: (717) 252-1200 | Bret Daniels, MD 6415 Lincoln Hwy, Wrightsville, PA 17368-9697 Ph: (717) 252-1200 |
News Archive
Gilead Sciences today announced topline results from two Phase 3 studies, FISSION and NEUTRINO, evaluating a 12-week course of the once-daily nucleotide sofosbuvir in combination with ribavirin (FISSION) and in combination with ribavirin and pegylated interferon (NEUTRINO) among treatment-naïve patients with chronic hepatitis C virus (HCV) infection.
Patients seeking to conserve privacy and personal dignity - i.e. anyone who's ever been forced to wear a traditional hospital gown that often reveal too much - may soon bid adieu peek-a-book hospital garb. Indeed, researchers from the University of Montreal have designed a revolutionary healthcare garment that preserves modesty.
Following a recent recall of potentially contaminated non-sterile alcohol prep pads, the U.S. Food and Drug Administration today reminded health care professionals about the safe use of non-sterile alcohol prep pads to clean and disinfect the surface of the skin.
Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine, have announced the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever study using patients' cells carrying an engineered T cell receptor to treat HIV (SL9 HA-GAG-TCR). The trial may have important implications in the development of new treatments for HIV potentially slowing – or even preventing – the onset of AIDS.
› Verified 6 days ago
Dr. Robert C Matylewicz Jr., D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 1166 Hilts Road, Wrightsville, PA 17368 Phone: 888-852-6672 Fax: 305-891-4228 |